Disease Markers / 2017 / Article / Tab 1 / Review Article
The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis Table 1 Basic characteristics of eligible studies.
First author Year Country Sample size Disease stage Drugs Method Cut-off value HR for OS HR for PFS Correlation coefficient Drug sensitivity test Follow-up times Ichikawa [31 ] 2006 Japan 59 Late S-1 RT-PCR Median 1.08 (0.97 to 1.21) 2 years Jeung [32 ] 2011 Korea 75 Late S-1 RT-PCR Median 0.97 (0.47 to 2.00) 1.1 (0.68 to 1.78) 4 years Koizumi [33 ] 2010 Japan 65 Late S-1 RT-PCR 1.9 (0.88 to 4.09) 3 years Matsubara [19 ] 2008 Japan 137 Locally advanced or late S-1, 5-FU, cisplatin + S-1 or irinotecan RT-PCR MA: 2.04 (1.37 to 3.02) 7 years Sasako [34 ] 2015 Japan 401 Stage II, III, R0 resection S-1 RT-PCR 33.3rd, 50th, or 66.7th percentiles MA: 0.66 (0.44 to 1.01) 5 years Yamada [35 ] 2013 Japan 304 Late 5FU, cisplatin + irinotecan, S-1 RT-PCR Median All: 0.95 (0.75 to 1.20); 1.00 (0.80 to 1.26) (all); 3 years Tsuburaya [40 ] 2016 Japan 106 Locally advanced or late S-1 or S-1 + irinotecan RT-PCR Median MA: 1.33 (0.87 to 2.02) 3 years Hisamitsu [13 ] 2004 Japan 111 T3 stage, R0 resection UFT IHC Percentage 1.03 (0.27 to 3.98) 5 years Miyamoto [36 ] 2000 Japan 41 Late S-1 IHC Intensity 0.86 (0.27 to 2.73) 2 years Oeda [37 ] 2006 Japan 221 Stages I to IV UFT, MMC + 5-FU IHC Proportion 1.44 (0.86 to 2.40) 5 years Fakhrejahani [38 ] 2007 Japan 87 Stages I to IV 5-FU RT-PCR −0.401 HDRA Inada [20 ] 2000 Japan 34 Locally advanced 5-FU Enzymatic assay −0.152 HDRA Ishikawa [39 ] 2000 Japan 41 Locally advanced 5-FU RT-PCR and enzymatic assay −0.41 (mRNA) MTT assay Terashima [15 ] 2003 Japan 67 Stages I to IV 5-FU Enzymatic assay −0.351 ATP assay Fujiwara [41 ] 2002 Japan 58 Stages I to IV 5-FU RT-PCR −0.458 ATP assay
Note . 5-FU: 5-fluorouracil; UFT: uracil/tegafur
